Skip to main content
. 2020 Dec 23;11:591269. doi: 10.3389/fimmu.2020.591269

Figure 2.

Figure 2

CD24+CD38hi B cells increase significantly in HBV patients during Peg-IFNα-2b therapy. Naive HBeAg-positive CHB patients were divided into two groups, one receiving Peg-IFNα-2b alone and one receiving Peg-IFNα-2b in combination with adefovir-dipivoxil, in order to simulate patients undergoing treatment with NUCs. Data were quantified from blood samples during routine visits to hepatitis clinics (weeks 0, 4, 12, 24, 36, and 48) and during follow-up (weeks 60 and 72). (A) Representative density plots showing CD24 and CD38 expression as well as CD27 and CD38 expression on gated CD19+B cells at each time point during Peg-IFNα-2b therapy. (B) Percentage analysis of CD19+B cells from HBV patients at 0-72w during Peg-IFNα-2b therapy. n = 75–90. Unpaired t test. (C) Percentage analysis of CD24+CD38hi B cells and CD27+CD38hi B cells from HBV patients at 0-72 week during PEG-IFNα-2b therapy. n = 47. Unpaired t test. (D) Cell numbers of CD24+CD38hiB cells and CD27+CD38hi B cells from HBV patients at 0-72w during PEG-IFNα-2b therapy. n = 47. Unpaired t test. Significant differences are shown in (C, D) indicating differences compared with the data at 0w. Mean ± SEM, **P < 0·01, ***P < 0·005, ****P < 0·0001.